Inhibition of PCSK9 synthesis via RNA interference

Børge G Nordestgaard
Professor, Chief Physician, MD, DMSc

Conflict of Interest Disclosure: the Danish tax payer
Consultancies or talks sponsored by AstraZeneca, Omthera, Sanofi, Regeneron, Ionis, Aegerion, Dezima, Fresenius, B Braun, Kaneka, Amgen, Kowa, Denka Seiken
PCSK9 inhibition

Extracellular

LDL

LDL-R

PCSK9

Extracellular & intracellular

Antibodies

RNA interference
Inclisiran
Inhibition of PCSK9 synthesis by RNA interference

50-60% LDL-C↓ over 3-6 months
Injections 2-3x per year

NonHDL-C↓ less than LDL-C↓
Remnant-C↑ ?
HDL-C↑ Good or bad?
Lp(a)↓ Important?

Serious adverse events↑ ?
Liver enzymes↑ ?
Myalgia ?

Side effect
Mild injection-site reaction

Effect
None?
Long-term studies of inclisiran

Inhibition of PCSK9 synthesis by RNA interference

LDL-C ↓ sustainable?  CVD benefit?  Mortality benefit?


Effect

Mild injection-site reaction

Side effect